ReviewExpert opinion on investigational drugs2017
Perspectives of HER2-targeting in gastric and esophageal cancer.
Review in Expert opinion on investigational drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review.Journal of gastrointestinal cancer · 2021Pooled it
- Trial
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Differentiating borderline HER2-expressing and HER2-positive cancers from other subtypes using serum urokinase plasminogen activator.British journal of cancer · 2026Article
- EGFL6 predicts unfavorable prognosis and serves as a potential indicator in esophageal carcinoma.Discover oncology · 2026Article
- Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer.Gastroenterology report · 2026Review
- Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective.ImmunoTargets and therapy · 2026Review
- Article
- Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects.Molecular pharmaceutics · 2024Review
- Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer.World journal of gastrointestinal oncology · 2024Review
- Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.International journal of clinical oncology · 2024Article
- Article
- Prediction of HER2 status via random forest in 3257 Chinese patients with gastric cancer.Clinical and experimental medicine · 2023Article
- Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review.Current oncology (Toronto, Ont.) · 2023Review
- Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review.Journal of thoracic disease · 2023Review
- Targeting EFNA1 suppresses tumor progression via the cMYC-modulated cell cycle and autophagy in esophageal squamous cell carcinoma.Discover oncology · 2023Article
- Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.International journal of molecular sciences · 2022Review
- Article
- Novel Drug Delivery Systems as an Emerging Platform for Stomach Cancer Therapy.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe blockade of HER2 signaling has significantly improved the outlook for esophagogastric cancer patients. However, targeting HER2 still remains challenging due to complex biology of this receptor in gastric and esophageal cancers. Areas covered: Here, we review complex HER2 biology, current methods of HER2 testing and tumor heterogeneity of gastroesophageal cancer. Ongoing and completed clinical research data are discussed. Expert opinion: HER2 overexpression is a validated target in gastroesophageal cancer, with therapeutic implications resulting in prolonged survival when inhibited in the front-line setting. With standardized HER2 testing in gastro-esophageal cancer, the ongoing trials are testing newer agents and combinations including combination of anti-HER2 antibodies with immunotherapy. Clonal heterogeneity and emergence of resistance will challenge our approach to treating these patients beyond the frontline settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.